Secondary immunodeficiency in lymphoproliferative malignancies.
Secondary immunodeficiencies occur as a consequence of various diseases, including hematological malignancies, and the use of pharmacological therapies, such as immunosuppressive, anti‐inflammatory, and biological drugs. Infections are the main cause of morbidity and mortality in multiple myeloma (M...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2016
|
| _version_ | 1797051356361523200 |
|---|---|
| author | Friman, V Winqvist, O Blimark, C Langerbeins, P Chapel, H Dhalla, F |
| author_facet | Friman, V Winqvist, O Blimark, C Langerbeins, P Chapel, H Dhalla, F |
| author_sort | Friman, V |
| collection | OXFORD |
| description | Secondary immunodeficiencies occur as a consequence of various diseases, including hematological malignancies, and the use of pharmacological therapies, such as immunosuppressive, anti‐inflammatory, and biological drugs. Infections are the main cause of morbidity and mortality in multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) patients. Recent advances in treatment have prolonged the duration of remission and the time between relapse phases in MM and CLL patients. However, managing multiple relapses and the use of salvage therapies can lead to cumulative immunosuppression and a higher risk of infections. The pathogenesis of immune deficiency secondary to lymphoproliferative malignancy is multifactorial including disease‐and treatment‐related factors. Supportive treatment, including early vaccination, anti‐infective prophylaxis, and replacement immunoglobulin, plays a key role in preventing infections in MM and CLL. This article provides an overview of the basic immunology necessary to understand the pathogenesis of secondary immunodeficiency and the infectious complications in MM and CLL. We also discuss the evidence supporting the role of prophylactic replacement immunoglobulin treatment in patients with antibody failure secondary to MM and CLL and the indications for its use. |
| first_indexed | 2024-03-06T18:18:21Z |
| format | Journal article |
| id | oxford-uuid:056c06b6-cb68-48c4-b4c0-faff73493630 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:18:21Z |
| publishDate | 2016 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:056c06b6-cb68-48c4-b4c0-faff734936302022-03-26T08:57:05ZSecondary immunodeficiency in lymphoproliferative malignancies.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:056c06b6-cb68-48c4-b4c0-faff73493630EnglishSymplectic Elements at OxfordWiley2016Friman, VWinqvist, OBlimark, CLangerbeins, PChapel, HDhalla, FSecondary immunodeficiencies occur as a consequence of various diseases, including hematological malignancies, and the use of pharmacological therapies, such as immunosuppressive, anti‐inflammatory, and biological drugs. Infections are the main cause of morbidity and mortality in multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) patients. Recent advances in treatment have prolonged the duration of remission and the time between relapse phases in MM and CLL patients. However, managing multiple relapses and the use of salvage therapies can lead to cumulative immunosuppression and a higher risk of infections. The pathogenesis of immune deficiency secondary to lymphoproliferative malignancy is multifactorial including disease‐and treatment‐related factors. Supportive treatment, including early vaccination, anti‐infective prophylaxis, and replacement immunoglobulin, plays a key role in preventing infections in MM and CLL. This article provides an overview of the basic immunology necessary to understand the pathogenesis of secondary immunodeficiency and the infectious complications in MM and CLL. We also discuss the evidence supporting the role of prophylactic replacement immunoglobulin treatment in patients with antibody failure secondary to MM and CLL and the indications for its use. |
| spellingShingle | Friman, V Winqvist, O Blimark, C Langerbeins, P Chapel, H Dhalla, F Secondary immunodeficiency in lymphoproliferative malignancies. |
| title | Secondary immunodeficiency in lymphoproliferative malignancies. |
| title_full | Secondary immunodeficiency in lymphoproliferative malignancies. |
| title_fullStr | Secondary immunodeficiency in lymphoproliferative malignancies. |
| title_full_unstemmed | Secondary immunodeficiency in lymphoproliferative malignancies. |
| title_short | Secondary immunodeficiency in lymphoproliferative malignancies. |
| title_sort | secondary immunodeficiency in lymphoproliferative malignancies |
| work_keys_str_mv | AT frimanv secondaryimmunodeficiencyinlymphoproliferativemalignancies AT winqvisto secondaryimmunodeficiencyinlymphoproliferativemalignancies AT blimarkc secondaryimmunodeficiencyinlymphoproliferativemalignancies AT langerbeinsp secondaryimmunodeficiencyinlymphoproliferativemalignancies AT chapelh secondaryimmunodeficiencyinlymphoproliferativemalignancies AT dhallaf secondaryimmunodeficiencyinlymphoproliferativemalignancies |